Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Accepted Preprint first posted online on 19 August 2008

European Journal of Endocrinology 2008;159:569.

DOI: 10.1530/EJE-08-0402
Copyright © 2008 by European Society of Endocrinology
This Article
Right arrow Accepted manuscript (PDF)
Right arrow All Versions of this Article:
EJE-08-0402v1
159/5/569    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Reimondo, G.
Right arrow Articles by Terzolo, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reimondo, G.
Right arrow Articles by Terzolo, M.

CLINICAL STUDY

The combined low-dose dexamethasone suppression corticotropin releasing-hormone test as a tool to rule out Cushing's syndrome

Giuseppe Reimondo, Silvia Bovio, Barbara Allasino, Silvia De Francia, Barbara Zaggia, Ilaria Micossi, Angela Termine, Francesca De Martino, Piero Paccotti, Francesco Di Carlo, Alberto Angeli and Massimo Terzolo

G Reimondo, Dipartimento di Scienze Cliniche e Biologiche, Universita  di Torino, ASO San Luigi, Medicina Interna I, Orbassano, Italy
S Bovio, Dipartimento di Scienze Cliniche e Biologiche, Universita  di Torino, ASO San Luigi, Medicina Interna I, Orbassano, Italy
B Allasino, Dipartimento di Scienze Cliniche e Biologiche, Universita  di Torino, ASO San Luigi, Medicina Interna I, Orbassano, Italy
S De Francia, Dipartimento di Scienze Cliniche e Biologiche, Universita  di Torino, ASO San Luigi, Farmacologia, Orbassano, Italy
B Zaggia, Dipartimento di Scienze Cliniche e Biologiche, Universita  di Torino, ASO San Luigi, Medicina Interna I, Orbassano, Italy
I Micossi, Dipartimento di Scienze Cliniche e Biologiche, Universita  di Torino, ASO San Luigi, Medicina Interna I, Orbassano, Italy
A Termine, Dipartimento di Scienze Cliniche e Biologiche, Universita  di Torino, ASO San Luigi, Medicina Interna I, Orbassano, Italy
F De Martino, Dipartimento di Scienze Cliniche e Biologiche, Universita  di Torino, ASO San Luigi, Farmacologia, Orbassano, Italy
P Paccotti, Dipartimento di Scienze Cliniche e Biologiche, Universita  di Torino, ASO San Luigi, Medicina Interna I, Orbassano, Italy
F Di Carlo, Dipartimento di Scienze Cliniche e Biologiche, Universita  di Torino, ASO San Luigi, Farmacologia, Orbassano, Italy
A Angeli, Dipartimento di Scienze Cliniche e Biologiche, Universita  di Torino, ASO San Luigi, Medicina Interna I, Orbassano, Italy
M Terzolo, Dipartimento di Scienze Cliniche e Biologiche, Universita  di Torino, ASO San Luigi, Medicina Interna I, Orbassano, Italy

Correspondence: Giuseppe Reimondo, Email: giuseppe.reimondo{at}unito.it

Abstract

Objective: It remains to be evaluated whether the combined low-dose dexamethasone suppression corticotropin releasing-hormone test (LDDST-CRH test) may add to the diagnostic approach of patients suspected to have Cushing's syndrome (CS). Aim of the present study was to evaluate whether the LDDST-CRH test may have a place in the diagnostic strategy of CS.

Design: Prospective evaluation of a consecutive series of patients with suspected CS from 2004 to 2006.

Methods: All the subjects underwent the same screening protocol including 1-mg-dexamethasone suppression test (DST), 24-hour urinary free cortisol (UFC) and midnight serum cortisol, followed by the LDDST-CRH test. Plasma dexamethasone concentration was measured 2 h after the last dose of dexamethasone.

Results: 16 patients had CS while in the remaining 15 subjects CS was excluded. Even if non statistically significant, the sensitivity and the negative predictive value of the cortisol 15 min after CRH was better than the other tests; on the other hand, the test specificity was lower. All of the patients classified as indeterminate were correctly diagnosed by the LDDST-CRH test. Nevertheless, the repeat assessment of the screening tests and the active follow-up gave the same correct results. In all of the patients misclassified by the LDDST-CRH the plasma dexamethasone concentrations were in the normal range.

Conclusions: Based on our findings, we suggest that LDDST-CRH test may still find a place as a rule-out procedure in patients who present with indeterminate results after screening and may be unavailable to repeat testing during follow-up.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2008 European Society of Endocrinology.